Dr Simon Lord

portrait photo of a man
Against Breast Cancer Junior Research Fellow



I am a Senior Clinical Researcher in Experimental Cancer Therapeutics based in the Early Phase Cancer Trials Unit and also a consultant medical oncologist at the Oxford Cancer Centre.

I undertook my clinical training in Southampton, Leeds and Oxford and in 2010 was awarded a CRUK Clinical Research Fellowship with Professor Adrian Harris at the Weatherall Institute of Molecular Medicine in Oxford. Here I earned a DPhil for my work investigating therapeutic approaches to target mitochondria and defined two types of metabolic response to the diabetes drug, metformin, in breast cancer. This complex clinical study of breast cancer patients taking metformin integrated novel imaging, genetic and metabolic assays and will hopefully be a key step in repurposing this drug as a potential cancer therapy.

Associated courses
Research interests

My clinical research interests focus on the development of new drugs to treat breast cancer and I am principal and chief investigator on a number of clinical trials of novel therapies and cancer imaging techniques. I have an active collaborative ‘laboratory to clinic’ research programme which uses genetic and metabolic approaches and tumour cells grown directly from patient samples to characterise the behaviour of breast cancers that arise in patients with obesity and diabetes. The Against Breast Cancer Junior Research Fellowship will be instrumental in supporting this work with a view to identifying promising drug targets to assess in future clinical trials.

Selected publications

Lord S, Cheng W, Liu D, Gaude E, Haider S, Metcalf T, Patel N, Teoh EJ, Gleeson, F, Bradley K, Wigfield S, Zois C, McGowan D, Ah-See M, Thompson A, Sharma A, Bidaut L, Pollak M, Roy PG, Karpe F, James T, English R, Adams R, Campo L, Ayers L, Snell C, Roxanis I, Frezza C, Fenwick JD, Buffa FM, Harris AL. Integrated pharmacodynamic analysis identifies two metabolic adaption pathways to metformin in breast cancer. Cell Metabolism. 2018. Epub ahead of print.

Morotti M, Dass PH, Harris AL, Lord S. Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients. Eur J Drug Metab Pharmacokinet. 2018 Apr;43(2):137-153.

Hall PS, Lord S, Collinson  M, Marshall M, Jones M, Lowe, C, Howard H, Swinson D, Velikova, G, Anthoney A, Roy, R, Dent J, Cheeseman S, Last K, Seymour MT. A randomised phase 2 trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO). Br J Cancer. 2017 Feb;116(4):464-471.

Lord S, Funes JM, Harris AL, Qunitela-Fandino M. Antiangiogenic resistance and cancer metabolism: opportunities for synthetic lethality. Curr Drug Targets. 2016 Dec; 17(15): 1714-1727.

Mehta S, Hughes NP, Li S, Jubb A, Adams R, Lord S, Koumakis L, van Stiphout R, Padhani A, Makris A, Buffa FM, Harris AL. Radiogenomics Monitoring Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment. EBioMedicine. 2016 July; 10: 109-116.